Tiziana Life Sciences (TLSA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences is expanding its Phase 2 trial for intranasal foralumab, a novel treatment for non-active secondary progressive multiple sclerosis (SPMS), to include prestigious U.S. medical centers like Yale and Johns Hopkins. This move aims to address the significant unmet need for SPMS therapies by leveraging top-tier research facilities and minimizing PET scan variability. Tiziana’s innovative approach targets inflammation without systemic immune suppression, underscoring its potential in treating complex neurodegenerative diseases.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.